Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 10,901–11,000 of 15,747
Fei, Y., Lin, Y., Liu, P., Zhong, K., Gao, Y., Ma, Q., Zhou, Z., Luo, S., Hu, R., & Cheng, Q. (2026) · ACS Nano · doi:10.1021/acsnano.6c03013 · Cited by 4
Antonini, C., Calandrini, S., & Bianconi, F. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07395-2 · Cited by 3
“According to [18], immunity is acquired about 14 days after receiving the vaccine.”
BackgroundAtiquzzaman, M., Zheng, Y., Er, L., Djurdjev, O., Singer, J., Krajden, M., Balamchi, S., Thomas, D., Hladunewich, M., Oliver, M. J., et al. (2023) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581231181032 · Cited by 3
Lu, N., Li, Z., Su, D., Chen, J., Zhao, J., Gao, Y. H., Liu, Q., Liu, G., Luo, X., Luo, R., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124344 · Cited by 4
Cell‐Penetrating Peptides for Nucleic Acid Delivery – An Update
Vivès, É., Josse, E., Konate, K., Deshayes, S., & Boisguérin, P. (2022) · Wiley eBooks · doi:10.1002/9783527835997.ch14 · Cited by 4
Osaka, T., Yamamoto, Y., Takehisa, S. O. M. A., Yanagisawa, N., & Nagata, S. (2023) · Microorganisms · doi:10.3390/microorganisms11020471 · Cited by 3
A FRET-based toolkit for quantifying lipid incorporation into nanoparticles
Rosales, P. D., Viravalli, A., Schneider, A., & Boehnke, N. (2025) · Nanoscale · doi:10.1039/d5nr03734d · Cited by 3
The Rise of RNA-Based Therapeutics: Recent Advances and Therapeutic Potential
Srivastava, S. P., Rai, V., Shukla, A., Trivedi, A., Gupta, Y. A., & Khan, S. (2024) · Journal for Research in Applied Sciences and Biotechnology · doi:10.55544/jrasb.2.6.31 · Cited by 3
“The mRNA vaccines by Pfizer-BioNTech and Moderna demonstrated high efficacy in preventing COVID-19 infection and severe disease (32,33).”
BackgroundForecasting Mortality Trends: Advanced Techniques and the Impact of COVID-19
Nalmpatian, A., Heumann, C., & Pilz, S. (2024) · Stats · doi:10.3390/stats7040069 · Cited by 3
Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis
Karampitsakos, Τ., Παπαϊωάννου, Ο., Dimeas, I. E., Tsiri, P., Sotiropoulou, V., Tomos, I. P., Papanikolaou, I. C., Katsaras, M., Kirgou, P., Daniil, Z. D., et al. (2022) · ERJ Open Research · doi:10.1183/23120541.00082-2022 · Cited by 3
Kosiorek, P., Stróż, S., Hryniewicz, A., et al. (2023) · Health Science Reports · doi:10.1002/hsr2.1172 · Cited by 3
BNT162b2 vaccine considerations for immunocompromised individuals: A global perspective
Jatoi, H. N., Abbas, S. G., Abbasi, M. S., Tauni, M. A., Ghazanfar, S., Malick, M. D. Z., Umar, M. F., Tahir, M. J., Asghar, M. S., & Ahmed, A. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.103796 · Cited by 2
“The trials showed a good vaccine safety profile with an efficacy of over 95% [CI: 90.3, 97.6] in adults aged 65 years or above and no adverse effects were reported [7,8].”
InfluentialBalian, S., Bailey, B. A., Abboud, S., Kim, Y., Humphries, D., Kambali, S., Kalangi, S. T., Jarvis, J., Dayal, L., Beiz, H., et al. (2023) · Journal of Investigative Medicine · doi:10.1177/10815589221149191 · Cited by 4
Design of Fragrance Formulations with Antiviral Activity Using Bayesian Optimization
Zhang, F., Hirama, Y., Onishi, S., et al. (2024) · Microorganisms · doi:10.3390/microorganisms12081568 · Cited by 3
“Vaccination is an effective preventive method, yet it carries the potential for causing side effects [4].”
BackgroundThree-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2Preprint
Zhou, R., Liu, N., Li, X., Peng, Q., Yiu, C.-K., Huang, H., Yang, D., Du, Z., Kwok, H., Au, K., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.09.491254 · Cited by 5
SARS-CoV-2 immunity and an overview of the COVID-19 vaccines
Marković, M. (2021) · Medicinski podmladak · doi:10.5937/mp72-33315 · Cited by 3
Targeting Acod1/itaconate in cancer therapy: Mechanisms and opportunities
Deng, T., Li, X., Wu, S., Kong, J., & Wu, X. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108139 · Cited by 4
Lim, S. H., Choi, S. H., Ji, Y. S., Kim, S. H., Kim, C. K., Yun, J., & Park, S. K. (2023) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13959 · Cited by 4
A Comprehensive Review on Types of Vaccines: From Classic to Cutting-Edge
Ahmad, S. (2023) · Vaccines & Vaccination Open Access · doi:10.23880/vvoa-16000164 · Cited by 3
Sharabrin, S. V., Krasnikova, S. I., Kisakov, D. N., Borgoyakova, M. B., Yakovlev, V. A., Tigeeva, E. V., Starostina, E. V., Litvinova, V. R., Kisakova, L. A., Vahitov, D. I., et al. (2026) · Vaccines · doi:10.3390/vaccines14010056 · Cited by 4
“Another important advantage is the efficient activation of both humoral and cellular virus-specific immunity, since the target protein is expressed endogenously from mRNA [12,13].”
Breakthroughs in mRNA vaccines and innovations in drug development
Wei, L., & Xue, Y. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-1058 · Cited by 3
Neonatal SARS‐CoV‐2 mRNA Vaccination Efficacy Is Influenced by Maternal Antibodies
Schumer, A., Bonney, E. A., Harby, E., & Majumdar, D. S. (2024) · American Journal of Reproductive Immunology · doi:10.1111/aji.70001 · Cited by 3
Yamada, M., Matsumoto, E., Thomas, C. P., Carlson, J. R., Klutts, J. S., Kumar, B., Streit, J. A., & Swee, M. L. (2021) · Transplantation Direct · doi:10.1097/txd.0000000000001193 · Cited by 3
Brief Overview of the Currently Available COVID-19 Vaccines
Krasilnikova, A. V. (2022) · Journal of Clinical and Health Sciences · doi:10.24191/jchs.v7i1.14658 · Cited by 3
SARS-COV-2 – the pandemic of the XXI century, clinical manifestations – neurological implications
Saceleanu, V. M., Moreanu, M.-S., Covache-Busuioc, R.-A., Mohan, A. G., & Ciurea, A.-V. (2022) · Journal of Medicine and Life · doi:10.25122/jml-2020-0151 · Cited by 3
“Compared to age samples, young people had higher immunity from vaccination than the elderly [108].”
BackgroundRecent applications of RNA therapeutic in clinics
Thi, H. T. H., & Than, V. T. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.015 · Cited by 3
Potter, D., Diep, J., Munro, C., et al. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03560-8 · Cited by 3
“KTRs were prioritised for vaccine administration, however, were not included in original vaccination trials [8, 9].”
BackgroundPrioritizing the First Doses of SARS-CoV-2 Vaccine to Save the Elderly: The Case Study of Italy
Pontrelli, G., Cimini, G., Roversi, M., Gabrielli, A., Salina, G., Bernardi, S., Rocchi, F., Simonetti, A., Giaquinto, C., Rossi, P., et al. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.684760 · Cited by 3
Burgess, L. H., Braithwaite, J. J., Singleton, E., Young, A. M., & Cooper, M. K. (2020) · HCA Healthcare Journal of Medicine · doi:10.36518/2689-0216.1228 · Cited by 5
Bordry, N., Mamez, A., Fedeli, C., Cantero, C., Jaksic, C., Ustero, P., Rayroux, C., Berra, G., Portillo, V., Puntel, M., et al. (2023) · Vaccines · doi:10.3390/vaccines11081284 · Cited by 3
“Studies assessing the Pfizer-BioNTech BNT162b2 mRNA and Moderna mRNA-1273 vaccines showed that they have 95% efficacy in preventing severe COVID-19, but these trials systematically excluded immunocompromised patients (ICPs) [2,3].”
BackgroundCOVID-19 in Patients with Chronic Lymphocytic Leukemia: What Have We Learned?
Harel, R., & Itchaki, G. (2023) · Acta Haematologica · doi:10.1159/000534540 · Cited by 4
Lorenz, P., Steinbeck, F., Mai, F., Reisinger, E. C., & Müller‐Hilke, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1192395 · Cited by 3
“vaccine BNT162b2, Comirnaty from Pfizer/BioNTech (3); and mRNA-1273 fromModerna (4);).”
Measuring SARS‐CoV ‐2 aerosolization in rooms of hospitalized patients
Yan, K. K.-L., Lin, J., Albaugh, S., Yang, M., Wang, E., Cyberski, T. F., Abasiyanik, M. F., Wroblewski, K., O’Connor, M. F., Klock, A., et al. (2022) · Laryngoscope Investigative Otolaryngology · doi:10.1002/lio2.802 · Cited by 2
“While many HCWs are protected by vaccination, the efficacy of SARSCoV-2 vaccinations is not 100% and studies have demonstrated symptomatic breakthrough infections in fully vaccinated HCWs.(3,4) Evidence supports transmission of SARS-CoV-2 through the air, although controversies over parameters that govern spread remai…”
BackgroundCOVID-19 Vaccination in Patients with Classic Kaposi’s Sarcoma
Indini, A., Tourlaki, A., Grossi, F., Gambini, D., & Brambilla, L. (2021) · Vaccines · doi:10.3390/vaccines9060632 · Cited by 3
“In fact, from a safety standpoint, results of the main mRNA vaccines’ trials have not demonstrated vaccinerelated serious adverse events, and have provided the highest protection rates [9].”
BackgroundVaccinations or Non-Pharmaceutical Interventions: Safe Reopening of Schools in EnglandPreprint
Cuesta-Lazaro, C., Quera-Bofarull, A., Aylett-Bullock, J., Lawrence, B., Fong, K. J., Icaza-Lizaola, M., Sedgewick, A., Truong, H., Vernon, I., Williams, J. M., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-955495/v1 · Cited by 8
Ferorelli, D., Spagnolo, L., Marrone, M., Corradi, S., Silvestre, M. E. A., Misceo, F., Bianchi, F. P., Stefanizzi, P., Solarino, B., Dell'Erba, A. S., et al. (2021) · Vaccines · doi:10.3390/vaccines9050423 · Cited by 3
“6% recommending that “with such a highly protective first dose, the benefits derived from a scarce supply of vaccine could be maximized by deferring second doses until all priority group members are offered at least one dose” [30].”
BackgroundKhan, S., Ullah, I., Rizwan, M., Zhang, Y., Zeb, A., Ubaidullah, Hamza, A., Zhang, S., Lü, X., & Feng, X. (2025) · Virology Journal · doi:10.1186/s12985-025-02982-6 · Cited by 5
Mataix, R. P., Morillo, J. S. G., & Martín, J. M. S. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2024.12.006 · Cited by 3
Jamaati, H., Karimi, S., Arshi, S., Zahraei, S. M., Panahi, Y., Nouri, F., Hajimoradi, M., Hasanzade, A., Mokhtari, M., Tayeri, K., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1504973 · Cited by 3
Önal, U., & Akalın, H. (2021) · Balkan Medical Journal · doi:10.5152/balkanmedj.2021.20197 · Cited by 3
Schiaroli, E., Gidari, A., Brachelente, G., Bicchieraro, G., Spaccapelo, R., Bastianelli, S., Pierucci, S., Busti, C., Pallotto, C., Malincarne, L., et al. (2023) · Journal of Clinical Virology · doi:10.1016/j.jcv.2023.105584 · Cited by 5
Association of COVID-19 vaccination with duration of hospitalization in older adults in Hong Kong
Chen, D., Cowling, B. J., Ainslie, K. E. C., Lin, Y., Wong, J. Y., Lau, E. H. Y., Wu, P., & Nealon, J. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.02.074 · Cited by 3
COVID-19 Vaccine in Veterans with Multiple Sclerosis: Protect the Vulnerable
Bagnato, F. R. (2021) · Federal Practitioner · doi:10.12788/fp.0113 · Cited by 3
COVID-19 vaccination and leprosy–A UK hospital-based retrospective cohort study
de Barros, B., Pierce, R., Sprenger, C., Ong, E. L. H., & Walker, S. L. (2023) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0011493 · Cited by 4
“The BNT162b2 is RNA-based vaccine developed by Pfizer BioNTech, and it elicits neutralising antibodies and robust antigen-specific CD8 and Th1-type CD4 T-cell responses [18].”
BackgroundAssessing parameter sensitivity in a university campus COVID-19 model with vaccinations
Childs, M. R., & Wong, T. E. (2023) · Infectious Disease Modelling · doi:10.1016/j.idm.2023.04.002 · Cited by 3
“have shown a protection from symptomatic infection (Baden et al., 2021; Polack et al., 2020; Sadoff et al., 2021).”
Liang, B., Xiang, T., Wang, H., Li, Z., Quan, X., Feng, X., Li, S., Lu, S., Fan, L., Xu, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.966098 · Cited by 4
“divided into four groups based on previous COVID-19 exposure and vaccination: (1) HC-baseline: healthy individuals without vaccination, (N=14); (2) HC-vaccination: healthy individuals with vaccination, (N=55); (3) SR-baseline: SARSCoV-2 recovered individuals without vaccination, (N=40); (4) SR-vaccination: SARS-CoV-2…”
MethodOh, D., Hölzer, M., Börnigen, D., Paraskevopoulou, S., Duwe, S. C., Budt, M., Kerber, R., Mikołajewska, A., Böttcher, S., Seifried, J., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-01093-1 · Cited by 5
Impact of memory T cells on SARS-CoV-2 vaccine response in hematopoietic stem cell transplant
VanOudenhove, J., Liu, Y., Nelakanti, R. V., Kim, D., Busarello, E., Ovalle, N. T., Qi, Z., Mamillapalli, P., Siddon, A. J., Bai, Z., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0320744 · Cited by 4
“SARS-CoV-2 mRNA vaccines, including Pfizer’s BNT162b2 and Moderna’s mRNA-1273, were made available under Emergency Use Authorization (EUA) in December 2020 after they showed a 95% and 94.1% efficacy, respectively, in preventing severe symptomatic COVID-19 infection [7,8].”
InfluentialWatschinger, C., Stampfel, G., Zollner, A., Hoog, A., Rössler, A., Reiter, S., Dax, K., Kimpel, J., Tilg, H., Antlanger, M., et al. (2023) · Viruses · doi:10.3390/v16010001 · Cited by 3
“Vaccines against SARS-CoV-2 such as BNT162b2 or mRNA-1273 have proven to mount excellent immunogenicity in the general immunocompetent population [19,20].”
BackgroundAn update on vaccine status and the role of nanomedicine against SARS‐CoV‐2: A narrative review
Tajnur, R., Rezwan, R., Aziz, M. A., & Islam, M. S. (2023) · Health Science Reports · doi:10.1002/hsr2.1377 · Cited by 2
“The job of impregnation of Ag‐NPs in face masks and air filters is to inactivate SARS‐CoV‐2.145 Influenza viruses can be inactivated when exposed to a mask containing CuO‐NPs.”
MethodInfluentialRiemma, G., Etrusco, A., Laganà, A. S., Torella, M., Vastarella, M. G., Corte, L. D., D’Amato, A., Verde, M. L., FRANCISCIS, P. D., & Cobellis, L. (2024) · Reproductive Sciences · doi:10.1007/s43032-024-01707-4 · Cited by 4
“The commercialization of the mRNA COVID-19 vaccine has deeply improved the quality of treatment for these patients [24].”
Sood, S., Matar, M. M., Kim, J., Kinsella, M., Rayavara, K., Signer, O., Henderson, J., Rogers, J. G., Chawla, B., Narvaez, B., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.065 · Cited by 3
Sanada, T., Honda, T., Higa, M., Yamaji, K., Yasui, F., & Kohara, M. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.12.012 · Cited by 4
“Among these vaccines, mRNA-based vaccines developed by Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) have been used globally [2, 3].”
Han, T. Y., Shim, D. H., Lee, Y. J., et al. (2023) · Annals of Dermatology · doi:10.5021/ad.22.118 · Cited by 3
COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study
Morgan, G., Casalino, S., Chowdhary, S., Frangione, E., Fung, C. Y. J., Lapadula, E., Arnoldo, S., Bearss, E., Binnie, A., Borgundvaag, B., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.03.030 · Cited by 3
Liu, J., Li, Y., Wang, M., & Yang, J. (2024) · World Journal of Virology · doi:10.5501/wjv.v13.i2.91286 · Cited by 4
Engelmann, R., Jaekel, N., Jotschke, S., Ludwig‐Kraus, B., Kraus, F. B., Kumari, N., Schulze, S., Hecker, M., Zahn, C., Al‐Ali, H. K., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009054 · Cited by 4
Campbell, E., Dobkin, J., Osorio, L., Kolloli, A., Ramasamy, S., Kumar, R., Sant’Angelo, D. B., Subbian, S., Denzin, L. K., & Anderson, S. (2023) · Vaccines · doi:10.3390/vaccines11040832 · Cited by 3
“The first approved SARS-CoV-2 vaccines were remarkably effective against the ancestral strain, with multiple clinical trials demonstrating vaccine effectiveness at preventing severe disease of over 90% [1,2].”
BackgroundRobinson, J. J., Zhang, D., Basak, P., Vaidya, A., Chatterjee, S., Bian, X., Kim, M., Lian, X., Sun, Y., Guerrero, E. D., et al. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c00631 · Cited by 5
(2021) · doi:10.1101/2021.07.28.21261200 · Cited by 3
“Even BNT162b2 (Pfizer/BioNTech), which showed high efficacy 65 against infections in the first trials [25] may provide a lower protection against new variants, as exemplified by the variant B.”
Progress on mRNA vaccines and lipid nanoparticles
Fan, Y., Yin, H., Li, Y., Xi, Y., Tang, X., Weng, Y., & Huang, Y. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-1093 · Cited by 3
Demmer, R. T., Wu, C. C. N., Kim, J. S., Sun, Y., Balte, P., Cushman, M., Boyle, R., Tracy, R. P., Styer, L. M., Bell, T. D., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf123 · Cited by 3
“Pfizer vaccine trial results demonstrated that infection rates did not start to decrease until ∼ 2 weeks following the first vaccine dose [27], and prior serostu-dies report that seropositivity following vaccination is not present in the majority of participants until 12 days after vaccination [28].”
Graham, J. (2021) · medRxiv · doi:10.1101/2021.03.06.21253058 · Cited by 2
Otomi, Y., Shinya, T., Kasai, H., et al. (2023) · Molecular Imaging and Radionuclide Therapy · doi:10.4274/mirt.galenos.2022.27136 · Cited by 3
Katoh, M., & Katoh, M. (2021) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2021.720577 · Cited by 3
“Economic stimulus packages of governments and interest rate policies of national banks to support firms, health care systems and households have been alleviating the global economic crisis caused by the COVID-19 pandemic but might increase the financial burdens of societies in the future owing to unprecedented rise of…”
BackgroundInfluentialBergami, F., Arena, F., Sammartino, J. C., Ferrari, A., Zavaglio, F., Zelini, P., Paolucci, S., Comolli, G., Percivalle, E., Lilleri, D., et al. (2022) · Vaccines · doi:10.3390/vaccines10111809 · Cited by 3
“The mRNA BNT162b2 vaccine [2] showed 95% protection against a SARS-CoV-2 infection in a phase II/III trial [3].”
BackgroundTargeting K-Ras Mutations Show Promise Towards Ending Ras’s “Undruggable” Era
Adams, P. D., & Muhoza, D. (2022) · Protein and Peptide Letters · doi:10.2174/0929866529666221003124202 · Cited by 3
van Dülmen, M., Muthmann, N., & Rentmeister, A. (2021) · Angewandte Chemie · doi:10.1002/ange.202100352 · Cited by 3
Lu, B., Ma, R., Xu, J., Zhang, Y., Guo, H., Chen, H., Miao, P., Qian, Y., Xu, B., Shen, Y., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1297770 · Cited by 4
Immediate protein expression from exogenous mRNAs in embryonic brain
Naruse, M., & Saito, T. (2022) · Scientific Reports · doi:10.1038/s41598-022-21668-5 · Cited by 3
Sukik, L., Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-19168-3 · Cited by 3
SARS-CoV-2 vaccinations in children and adolescents with rheumatic diseases
Sen, E. S., Julandani, D. A. A., & Ramanan, A. V. (2022) · Rheumatology · doi:10.1093/rheumatology/keac431 · Cited by 3
Ghosh, S., Chaudhury, D., Chowdhury, A., & Jana, N. K. (2025) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-96-4959-4_4 · Cited by 3
Peled, Y., Patel, J. K., Raanani, E., Ram, E., Fardman, A., Beigel, R., Atari, N., Kliker, L., Elkader, B. A., Mandelboim, M., et al. (2023) · Clinical Transplantation · doi:10.1111/ctr.15091 · Cited by 3
Ferrari, L., Ruggiero, A., Stefani, C., Benedetti, L., Piermatteo, L., Andreassi, E., Caldara, F., Zaçe, D., Pagliari, M., Ceccherini‐Silberstein, F., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-58597-4 · Cited by 2
“Systemic side effects were more often reported after the second vaccine dose compared with the first dose, but there was no evidence of an increased risk of adverse events or of a different pattern of side effects relative to general trial populations 30,31 .”
InfluentialDynamics of anti-SARS-CoV-2 seroconversion in individual patients and at the population level
Szewczyk-Dąbrowska, A., Budziar, W., Baniecki, K., Pikies, A., Harhala, M. A., Jędruchniewicz, N., Kaźmierczak, Z., Gembara, K., Klimek, T., Witkiewicz, W., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274095 · Cited by 3
Critical applications and prospects of RNA modification in mRNA vaccines
Liu, C., Peng, J., Zhang, M., Xiang, H., & Yi, C. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-0800 · Cited by 2
DNA-based vaccines: Advances, applications, and future prospects
Zhou, Z. P., Chen, Z. R., Bandara, R. A., Duan, R. C., Cao, H., Liu, J., & Hu, J. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2025.102025 · Cited by 9
“The COVID-19 pandemic catalyzed unprecedented investment and research in nucleic acid-based vaccines, resulting in the Emergency Use Authorization (EUA) of several mRNA vaccines 5,6 and Ad vector-based DNA vaccines.”
Endo-Lysosome-Targeted Nanoparticle Delivery of Antiviral Therapy for Coronavirus InfectionsPreprint
Petcherski, A., Tingley, B. M., Martin, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.08.539898 · Cited by 3
TWISTER PLOTS FOR TIME-TO-EVENT STUDIES
Zivich, P. N., Cole, S. R., & Breskin, A. (2021) · American Journal of Epidemiology · doi:10.1093/aje/kwab231 · Cited by 3
Jin, Z., Wu, J., Wang, Y., Huang, T., Zhao, K., Liu, J., Wang, H., Zhu, T., Gou, J.-B., Huang, H., et al. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.10.012 · Cited by 6
Vaccination policy and mortality from COVID-19 in the European Union
Agostini, E., Bloise, F., & Tancioni, M. (2024) · Econometrics Journal · doi:10.1093/ectj/utae005 · Cited by 7
Characterization of lipid nanoparticles using macro mass photometry: Insights into size and mass
Wu, J., Zhang, Y., Wu, Z., Townsend, J. A., Crooks, I., Watt, B., Baik, A. D., Cygnar, K. D., Qiu, H., & Li, N. (2025) · Analytica Chimica Acta · doi:10.1016/j.aca.2025.343944 · Cited by 7
Hebibi, H., Edeas, M. A., Cornillac, L., Beaudreuil, S., Achiche, J., Attaf, D., Saibi, S., Chazot, C., Ouaaz, F., & Canaud, B. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2010006 · Cited by 3
“A large study in a healthy population showed that a two-dose vaccination procedure reduced severe acute respiratory syndrome and subsequent death by greater than 90% [7].”
BackgroundThe Long-Term Immunogenicity of mRNABNT162b Third Vaccine Dose in Solid Organ Transplant Recipients
Zingaropoli, M. A., Guardiani, M., Dominelli, F., Tortellini, E., Garofalo, M., Dezza, F. C., Centofanti, A., Carillo, C., Napoli, A., Venuta, F., et al. (2024) · Vaccines · doi:10.3390/vaccines12030224 · Cited by 3
“In this context, mRNA-based vaccines have become the mainstay for the pandemic response, due to their ability to induce robust and protective humoral and cellular responses against SARS-CoV-2 [4,5].”
BackgroundGarcia‐Huidobro, D., Iturriaga, C., Pérez‐Mateluna, G., Fajuri, P., Severino, N., Urzua, M. D., Fraga, J. P., de la Cruz, J., Poli, M. C., Castro-Rodríguez, J. A., et al. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01278-3 · Cited by 3
“Vaccination has effectively reduced disease incidence and severity [2, 3], but the emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that are highly transmissible, despite causing less severe disease, continues to burden healthcare systems.”
BackgroundVaccines against COVID-19 using nanotechnology: a literature review
dos Santos, A. F., Fraga, A. S. A., Gomes, P., & Fagan, S. B. (2021) · Disciplinarum Scientia | Naturais e Tecnológicas · doi:10.37779/nt.v22i3.4097 · Cited by 3
Immunity waning after COVID vaccine booster vs. infection—better than expected
Khoury, J., Najjar‐Debbiny, R., Elemy, A., Jabbour, A. R., Haj, J., Abu-Sini, M., Yasin, R., Amin, M., Hellou, E., Nasrallah, N., et al. (2022) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2022.2097304 · Cited by 3
“Taking into consideration the excellent safety profile of the vaccines [11], and the risk in acute and long COVID syndrome [12], the importance of COVID vaccines cannot be over Figure 1.”
BackgroundImpact of Long-COVID on Health-related Quality of Life in Japanese COVID-19 PatientsPreprint
Tsuzuki, S., Miyazato, Y., Terada, M., Morioka, S., Ohmagari, N., & Beutels, P. (2021) · Research Square · doi:10.21203/rs.3.rs-948458/v1 · Cited by 3
Li, J., Nakagawa, T., Kojima, M., Nishikimi, A., Tokuda, H., Nishimura, K., Umezawa, J., Tanaka, S., Inoue, M., Ohmagari, N., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283658 · Cited by 5
“Clinical trials and observational studies have consistently demonstrated that messenger RNA (mRNA) based vaccines against COVID-19, such as BNT162b2, have an acceptable safety profile [7, 8], and two-dose vaccination of BNT162b2 has 95% (95% credible interval, 90.”
BackgroundPark, S.-H., Kim, Y., Kim, M.-A., Lee, Y. J., Seo, Y., Jin, H., & Lee, S. (2025) · Applied Sciences · doi:10.3390/app15084428 · Cited by 3
Carr, E. J., Townsley, H., Wu, M., Wilkinson, K. A., Hobson, P. S., Levi, D., Namjou, S., Mears, H. V., Hobbs, A., Ragno, M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.24.541920 · Cited by 3
Sex-biased immunogenicity of a mucosal subunit vaccine against SARS-CoV-2 in mice
Li, J., Hsu, K. S., Howe, S. E., Hoang, T. N., Zheng, X., Berzofsky, J. A., & Sui, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1386243 · Cited by 4
In Vivo Delivery Processes and Development Strategies of Lipid Nanoparticles
Cheng, J., Jian, L., Chen, Z., Li, Z., Yu, Y., & Wu, Y. (2024) · ChemBioChem · doi:10.1002/cbic.202400481 · Cited by 7
(2021) · doi:10.1101/2021.12.13.21267603 · Cited by 3
“, Reinisch W.(4), Zielinski C (7), Wiedermann U.”
Background
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.